Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Prednisolone · Flo-Pred, Orapred Odt

Small molecule · Agonist of glucocorticoid receptor (NR3C1) · developed by Sun Pharma Canada

Approved FDA, Jan 2008
7 Registered trials

What is Prednisolone?

Prednisolone is a synthetic adrenocortical glucocorticoid that binds and activates nuclear glucocorticoid receptors, altering gene expression to suppress inflammatory processes and lymphocyte numbers. It is used in ophthalmic, dermatologic, allergic, endocrine, hematologic, gastrointestinal and neoplastic conditions, and is studied in lymphoma, leukemia, prostate cancer and other settings.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Flo-Pred, Orapred Odt, Pred Forte, Prednisolone Acetate
Drug type
Small molecule
Targets
glucocorticoid receptor (NR3C1)
Mechanism
Agonist of glucocorticoid receptor (NR3C1)
Pathways
glucocorticoid receptor-mediated gene expression, inflammatory response inhibition, gluconeogenesis, lymphocyte depletion
Therapy area
Oncology, Ophthalmology
Developer
Sun Pharma Canada
In trials of
BNTX, MRK, NVS, OCUL, QURE, RARE, REGN, SNY
FDA status
Approved as Flo-Pred, Orapred Odt, Pred Forte (January 17, 2008), NDA022067 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 23, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05023304 Phase 4 Cataract Completed OCUL
NCT07365995 Phase 3 Metastatic Castration-resistant Prostate Cancer Recruiting BNTX
NCT06091254 Phase 3 Follicular Lymphoma (FL) Recruiting REGN
NCT05139316 Phase 3 Glycogen Storage Disease Type IA Completed RARE
NCT07387926 Phase 1/2 Acute Lymphoblastic Leukemia Recruiting NVS
NCT07190300 Phase 1/2 Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Recruiting NVS
NCT02904772 Phase 2 LPL Deficiency Withdrawn QURE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Lymphoblastic LeukemiaDiffuse Large B-cell Lymphoma (DLBCL)Follicular LymphomaLeukemia, Lymphoblastic, Acute, Philadelphia-PositiveMetastatic Castration-resistant Prostate CancerMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)CataractGlycogen Storage Disease Type IALPL Deficiency

Other drugs acting on NR3C1

Sources

Updated Nov 15, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.